IP Library Granted Patent US 8,796,270
Granted Patent B2
US 8,796,270 · App. 13/862,147 · Granted Aug 5, 2014

N-[6-(1H-indazol-6-yl)imidazo[1,2-A]pyridin-8-yl]-6-(morpholin-4-yl)pyridazin-3-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor

Inventor: Scott A. Mitchell (East Haven, CT)
Assignee: Gilead Connecticut, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,796,270
App. No.
13/862,147
Granted
Aug 5, 2014
Kind
B2
Abstract

An imidazopyridine having the structure or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

Claims (8)

1. A compound having the structure:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable vehicle selected from the group consisting of carriers, adjuvants, and excipients.

3. A method for inhibiting spleen tyrosine kinase activity in a human in need thereof, comprising administering to the human an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

4. The method according to claim 3 , wherein an effective amount of the compound, or a pharmaceutically acceptable salt thereof, is administered to the human intravenously, intramuscularly, parenterally, or orally.

5. A method for determining the presence or absence of spleen tyrosine kinase in a sample, comprising contacting the sample with a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and determining the presence or absence of spleen tyrosine kinase in the sample.

6. A method for inhibiting B-cell activity comprising contacting cells expressing spleen tyrosine kinase with a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

7. A method for inhibiting adenosine triphosphate hydrolysis, the method comprising contacting cells expressing spleen tyrosine kinase with a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2020
From: GILEAD CONNECTICUT, INC.
To: KRONOS BIO, INC.
Reel/Frame 053927/0969 →
MERGER AND CHANGE OF NAME Recorded Sep 17, 2020
From: COUGAR MERGER SUB, INC.; CGI PHARMACEUTICALS, INC.; CGI PHARMACEUTICALS, INC.
To: GILEAD CONNECTICUT, INC.
Reel/Frame 053799/0190 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2013
From: MITCHELL, SCOTT A.; CURRIE, KEVIN S.; BLOMGREN, PETER A.; KROPF, JEFFREY E.; LEE, SEUNG H.; XU, JIANJUN; STAFFORD, DOUGLAS G.
To: CGI PHARMACEUTICALS, INC.
Reel/Frame 031215/0767 →
MERGER Recorded Sep 16, 2013
From: CGI PHARMACEUTICALS, INC.
To: GILEAD CONNECTICUT, INC.
Reel/Frame 031215/0792 →
Continuity (5)
Continuation 12632151 · Dec 7, 2009
Provisional Application 61120590 · Dec 8, 2008
Provisional Application 61140535 · Dec 23, 2008
Provisional Application 61240983 · Sep 9, 2009
Related Publication 20130231330A1 · Sep 5, 2013